TG Therapeutics announces Clinical Trial of TGR-1202 in combination with Ibrutinib

TG Therapeutics announces Clinical Trial of TGR-1202 in combination with Ibrutinib

TG Therapeutics, Inc. announced today the initiation of a multi-center, Phase I trial to evaluate the safety and efficacy of the combination of TGR-1202 and ibrutinib for patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL):

money.cnn.com/news/newsfeed...

Other posts on TGR-1202:

healthunlocked.com/cllsuppo...

healthunlocked.com/cllsuppo...

Neil

Photo: Proteas are beautiful flowers

3 Replies

oldestnewest
  • ASH isn't just about medical breakthroughs; it's where financial fortunes are made and lost too...

    TG Therapeutics: Upcoming Data At ASH Conference Could Double Share Price:

    seekingalpha.com/article/27...

  • TGR-1202 is a PI3k-delta inhibitor similar to Gilead's Idelalisib. They also have TG-1102, which a glico- (sugar) shrouded anti-CD20 monoclonal anti-body being tested with Ibrutinib. It's sort of a souped up, 3rd generation Rituxan. Supposedly more efficient at lower dosage and hence less side effects.

  • Why not just use Zydelig (idelalisib) in combination with Gazyva (obinutuzimab)?

    I don't see the point in TG's approach, they are going against two major companies with FDA approved similar drugs already on the market...

    But in CLL more treatment choice is always better... and the devil is in the details.

You may also like...